Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,226 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group.
Dimopoulos MA, Terpos E, Chanan-Khan A, Leung N, Ludwig H, Jagannath S, Niesvizky R, Giralt S, Fermand JP, Bladé J, Comenzo RL, Sezer O, Palumbo A, Harousseau JL, Richardson PG, Barlogie B, Anderson KC, Sonneveld P, Tosi P, Cavo M, Rajkumar SV, Durie BG, San Miguel J. Dimopoulos MA, et al. Among authors: anderson kc. J Clin Oncol. 2010 Nov 20;28(33):4976-84. doi: 10.1200/JCO.2010.30.8791. Epub 2010 Oct 18. J Clin Oncol. 2010. PMID: 20956629 Review.
NF-kappa B as a therapeutic target in multiple myeloma.
Hideshima T, Chauhan D, Richardson P, Mitsiades C, Mitsiades N, Hayashi T, Munshi N, Dang L, Castro A, Palombella V, Adams J, Anderson KC. Hideshima T, et al. Among authors: anderson kc. J Biol Chem. 2002 May 10;277(19):16639-47. doi: 10.1074/jbc.M200360200. Epub 2002 Feb 28. J Biol Chem. 2002. PMID: 11872748 Free article.
Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma.
Richardson PG, Schlossman RL, Weller E, Hideshima T, Mitsiades C, Davies F, LeBlanc R, Catley LP, Doss D, Kelly K, McKenney M, Mechlowicz J, Freeman A, Deocampo R, Rich R, Ryoo JJ, Chauhan D, Balinski K, Zeldis J, Anderson KC. Richardson PG, et al. Among authors: anderson kc. Blood. 2002 Nov 1;100(9):3063-7. doi: 10.1182/blood-2002-03-0996. Blood. 2002. PMID: 12384400 Free article. Clinical Trial.
Molecular sequelae of proteasome inhibition in human multiple myeloma cells.
Mitsiades N, Mitsiades CS, Poulaki V, Chauhan D, Fanourakis G, Gu X, Bailey C, Joseph M, Libermann TA, Treon SP, Munshi NC, Richardson PG, Hideshima T, Anderson KC. Mitsiades N, et al. Among authors: anderson kc. Proc Natl Acad Sci U S A. 2002 Oct 29;99(22):14374-9. doi: 10.1073/pnas.202445099. Epub 2002 Oct 21. Proc Natl Acad Sci U S A. 2002. PMID: 12391322 Free PMC article.
The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications.
Mitsiades N, Mitsiades CS, Richardson PG, Poulaki V, Tai YT, Chauhan D, Fanourakis G, Gu X, Bailey C, Joseph M, Libermann TA, Schlossman R, Munshi NC, Hideshima T, Anderson KC. Mitsiades N, et al. Among authors: anderson kc. Blood. 2003 Mar 15;101(6):2377-80. doi: 10.1182/blood-2002-06-1768. Epub 2002 Nov 7. Blood. 2003. PMID: 12424198 Free article.
Novel biologically based therapies for multiple myeloma.
Munshi NC, Hideshima T, Chauhan D, Richardson P, Anderson KC. Munshi NC, et al. Among authors: anderson kc. Int J Hematol. 2002 Aug;76 Suppl 1:340-1. doi: 10.1007/BF03165281. Int J Hematol. 2002. PMID: 12430878 Review. No abstract available.
Multiple myeloma.
Anderson KC, Shaughnessy JD Jr, Barlogie B, Harousseau JL, Roodman GD. Anderson KC, et al. Hematology Am Soc Hematol Educ Program. 2002:214-40. doi: 10.1182/asheducation-2002.1.214. Hematology Am Soc Hematol Educ Program. 2002. PMID: 12446425 Review.
1,226 results